Validation Data Gallery

Filter: AllWBIPIHCIF/ICC

WB analysis of HT-29 using 11921-1-AP
HT-29 cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.
WB analysis of COLO 320 using 11921-1-AP
COLO 320 cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.
WB analysis of PC-3 using 11921-1-AP
PC-3 cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.
WB analysis of U-937 using 11921-1-AP
U-937 cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.
WB analysis of HepG2 using 11921-1-AP
HepG2 cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.
WB analysis of HeLa using 11921-1-AP
HeLa cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.
WB analysis of MDA-MB-453s using 11921-1-AP
MDA-MB-453s cells were subjected to SDS PAGE followed by western blot with 11921-1-AP (RASSF6 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.
IP experiment of HepG2 using 11921-1-AP
IP result of anti-RASSF6 (IP:11921-1-AP, 4ug; Detection:11921-1-AP 1:500) with HepG2 cells lysate 2400ug.
IHC staining of human ovary tumor using 11921-1-AP
Immunohistochemical analysis of paraffin-embedded human ovary tumor using 11921-1-AP (RASSF6 antibody) at dilution of 1:100 (under 10x lens).
IHC staining of human prostate cancer using 11921-1-AP
Immunohistochemical analysis of paraffin-embedded human prostate cancer using 11921-1-AP (RASSF6 antibody) at dilution of 1:100 (under 40x lens).
IHC staining of human prostate cancer using 11921-1-AP
Immunohistochemical analysis of paraffin-embedded human prostate cancer using 11921-1-AP (RASSF6 antibody) at dilution of 1:100 (under 10x lens).
IF Staining of HeLa using 11921-1-AP
Immunofluorescent analysis of Hela cells, using RASSF6 antibody 11921-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).

Featured Product
KD/KO Validated

RASSF6 Polyclonal antibody

RASSF6 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA

Cat No. 11921-1-AP

Publications(14)

Host / Isotype

Rabbit / IgG

Reactivity

human and More (1)

Applications

WB, IHC, IF/ICC, IP, CoIP, ELISA

Synonyms

Ras association domain-containing protein 6

Formulation: PBS, Azide, Glycerol

PBS, Azide, Glycerol

Conjugate: Unconjugated

Unconjugated

Size/Concentration:

-/ -

ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。

国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター（国内）に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。

保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換／補填対応を承ります。詳細はこちらをご覧ください。

Overview

Tested Applications
Product Information
Publications (14)
Protocols

データシート［PDF］を印刷

MSDS

Tested Applications

Positive WB detected in	HT-29 cells, COLO 320 cells, HeLa cells, HepG2 cells, MDA-MB-453s cells, PC-3 cells, U-937 cells
Positive IP detected in	HepG2 cells
Positive IHC detected in	human ovary tumor tissue, human prostate cancer tissue **Note: suggested antigen retrieval with TE buffer pH 9.0; () Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0***
Positive IF/ICC detected in	Hela cells

Recommended dilution

Application	Dilution
Western Blot (WB)	WB : 1:500-1:2000
Immunoprecipitation (IP)	IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)	IHC : 1:20-1:200
Immunofluorescence (IF)/ICC	IF/ICC : 1:10-1:100
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Published Applications

KD/KO	See 4 publications below
WB	See 10 publications below
IHC	See 7 publications below
IF	See 1 publications below
IP	See 2 publications below
CoIP	See 1 publications below

Product Information

11921-1-AP targets RASSF6 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human samples.

Tested Reactivity	human
Cited Reactivity	human, mouse
Host / Isotype	Rabbit / IgG
Class	Polyclonal
Type	Antibody
Immunogen	CatNo: Ag2565 Product name: Recombinant human RASSF6 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-300 aa of BC058835 Sequence: MAHQYPSWIFINEKTFITREQLNSLLKTYNIFYENQKNLHILYGETEDGKLIVEGMLDIFWGVKRPIQLKIQDEKPFSSFTSMKSSDVFSSKGMTRWGEFDDLYRISELDRTQIPMSEKRNSQEDYLPYHSNTLKPHAKDEPDSPVLYRTMSEAALVRKRMKPLMMDRKERQKNRASINGHFYNHEIENSPQDFALHIIFATGEQRRLKKTDIPLLQRLLQGPSEKNARIFLMDKDAEEISSDVAQYINFHFSLLESILQRLNEEEKREIQRIVTKFNKEKAIILKCLQNKLVIKTETTV 相同性解析による交差性が予測される生物種
Full Name	Ras association (RalGDS/AF-6) domain family member 6
Calculated molecular weight	369 aa, 43 kDa
Observed molecular weight	43 kDa
GenBank accession number	BC058835
Gene Symbol	RASSF6
Gene ID (NCBI)	166824
RRID	AB_874225
Conjugate	Unconjugated
Form
Form	Liquid
Purification Method	Antigen affinity purification
UNIPROT ID	Q6ZTQ3
Storage Buffer	PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3
Storage Conditions	Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Protocols

Product Specific Protocols
IF protocol for RASSF6 antibody 11921-1-AP	Download protocol
IHC protocol for RASSF6 antibody 11921-1-AP	Download protocol
IP protocol for RASSF6 antibody 11921-1-AP	Download protocol
WB protocol for RASSF6 antibody 11921-1-AP	Download protocol

Standard Protocols
Click here to view our Standard Protocols

Publications

Species	Application	Title
human	WB	Mol Cancer The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Authors - Hesson Luke B LB View Article
human	WB,IHC	J Genet Genomics RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma. Authors - Leilei Zheng KD Validated View Article
human	WB, IHC	World J Gastroenterol Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. Authors - Hui-Lin Ye View Article
human,mouse	WB,IHC	Oncotarget RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer. Authors - Rui Zhou View Article
human	WB	J Cell Physiol MiR-496 promotes migration and epithelial-mesenchymal transition by targeting RASSF6 in colorectal cancer. Authors - Hua Wang View Article
human	WB,IHC	Ann Surg Oncol Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery. Authors - Wen Yugang Y View Article

Validation Data Gallery

WB analysis of HT-29 using 11921-1-AP

WB analysis of COLO 320 using 11921-1-AP

WB analysis of PC-3 using 11921-1-AP

WB analysis of U-937 using 11921-1-AP

WB analysis of HepG2 using 11921-1-AP

WB analysis of HeLa using 11921-1-AP

WB analysis of MDA-MB-453s using 11921-1-AP

IP experiment of HepG2 using 11921-1-AP

IHC staining of human ovary tumor using 11921-1-AP

IHC staining of human prostate cancer using 11921-1-AP

IHC staining of human prostate cancer using 11921-1-AP

IF Staining of HeLa using 11921-1-AP

RASSF6 Polyclonal antibody

RASSF6 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA

-/ -

Tested Applications

Recommended dilution

Published Applications

Product Information

Protocols

Publications

The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.

RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma.

Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.

RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer.

MiR-496 promotes migration and epithelial-mesenchymal transition by targeting RASSF6 in colorectal cancer.

Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery.

Able™

Able^™